GHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
GH Research PLC (GHRS) is not a strong buy at this moment for a beginner investor with a long-term strategy. Despite some positive catalysts such as hedge fund interest and a promising product pipeline, the company's financial performance is weak, and the technical indicators do not suggest a strong entry point. Additionally, the lack of recent congress trading data and no active Intellectia Proprietary Trading Signals further reduce the immediate attractiveness of this stock.
The stock's MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 44.554, and while moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the stock has declined significantly in the regular market (-5.13%) and pre-market (-1.94%). Key support levels are at $14.651 and $14.216, which may act as potential downside targets.
Hedge funds are significantly increasing their positions (+735.47%).
Analysts have raised the price target to $40, citing optimism about GH001's long-term sales potential.
The company has a strong cash reserve of $280.7 million, which supports its ongoing R&D efforts.
The company reported a FY 2025 GAAP EPS of -$0.79, highlighting profitability challenges.
Competitor Helus Pharma is advancing rapidly with its own therapies, which could pose a threat to GHRS's market position.
No significant insider trading trends or congress trading data to indicate confidence from influential figures.
In Q4 2025, the company reported no revenue growth (0% YoY) and a significant drop in net income (-100% YoY). EPS declined sharply by -564.71% YoY, reflecting poor financial health. However, the company maintains a strong cash reserve of $280.7 million, which is a positive for its R&D activities.
RBC Capital raised the price target from $33 to $40 and maintained an Outperform rating, citing optimism about the company's long-term sales potential for GH001.
